Inactivated Vaccine Market Report

Global Inactivated Vaccine Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Mar 01, 2022
  • PAGES：136
  • REPORT CODE：GMM786248
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Inactivated Vaccine market report explains the definition, types, applications, major countries, and major players of the Inactivated Vaccine market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Johnson & Johnson (US)

    • Emergent BioSolutions (US)

    • MedImmune (US)

    • CSL Limited (Australia)

    • Serum Institute of India Pvt (India)

    • GlaxoSmithKline (UK)

    • Merck & Co (US)

    • Pfizer (US)

    • Sanofi Pasteur (France)

    • Astellas Pharma (Japan)

    By Type:

    • Pediatrics

    • Adults

    By End-User:

    • Hospital

    • Medical Center

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Inactivated Vaccine Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Inactivated Vaccine Outlook to 2028- Original Forecasts

    • 2.2 Inactivated Vaccine Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Inactivated Vaccine Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Inactivated Vaccine Market- Recent Developments

    • 6.1 Inactivated Vaccine Market News and Developments

    • 6.2 Inactivated Vaccine Market Deals Landscape

    7 Inactivated Vaccine Raw Materials and Cost Structure Analysis

    • 7.1 Inactivated Vaccine Key Raw Materials

    • 7.2 Inactivated Vaccine Price Trend of Key Raw Materials

    • 7.3 Inactivated Vaccine Key Suppliers of Raw Materials

    • 7.4 Inactivated Vaccine Market Concentration Rate of Raw Materials

    • 7.5 Inactivated Vaccine Cost Structure Analysis

      • 7.5.1 Inactivated Vaccine Raw Materials Analysis

      • 7.5.2 Inactivated Vaccine Labor Cost Analysis

      • 7.5.3 Inactivated Vaccine Manufacturing Expenses Analysis

    8 Global Inactivated Vaccine Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Inactivated Vaccine Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Inactivated Vaccine Export by Region (Top 10 Countries) (2017-2028)

    9 Global Inactivated Vaccine Market Outlook by Types and Applications to 2022

    • 9.1 Global Inactivated Vaccine Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Pediatrics Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Adults Consumption and Growth Rate (2017-2022)

    • 9.2 Global Inactivated Vaccine Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Medical Center Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Inactivated Vaccine Market Analysis and Outlook till 2022

    • 10.1 Global Inactivated Vaccine Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Inactivated Vaccine Consumption (2017-2022)

      • 10.2.2 Canada Inactivated Vaccine Consumption (2017-2022)

      • 10.2.3 Mexico Inactivated Vaccine Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Inactivated Vaccine Consumption (2017-2022)

      • 10.3.2 UK Inactivated Vaccine Consumption (2017-2022)

      • 10.3.3 Spain Inactivated Vaccine Consumption (2017-2022)

      • 10.3.4 Belgium Inactivated Vaccine Consumption (2017-2022)

      • 10.3.5 France Inactivated Vaccine Consumption (2017-2022)

      • 10.3.6 Italy Inactivated Vaccine Consumption (2017-2022)

      • 10.3.7 Denmark Inactivated Vaccine Consumption (2017-2022)

      • 10.3.8 Finland Inactivated Vaccine Consumption (2017-2022)

      • 10.3.9 Norway Inactivated Vaccine Consumption (2017-2022)

      • 10.3.10 Sweden Inactivated Vaccine Consumption (2017-2022)

      • 10.3.11 Poland Inactivated Vaccine Consumption (2017-2022)

      • 10.3.12 Russia Inactivated Vaccine Consumption (2017-2022)

      • 10.3.13 Turkey Inactivated Vaccine Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Inactivated Vaccine Consumption (2017-2022)

      • 10.4.2 Japan Inactivated Vaccine Consumption (2017-2022)

      • 10.4.3 India Inactivated Vaccine Consumption (2017-2022)

      • 10.4.4 South Korea Inactivated Vaccine Consumption (2017-2022)

      • 10.4.5 Pakistan Inactivated Vaccine Consumption (2017-2022)

      • 10.4.6 Bangladesh Inactivated Vaccine Consumption (2017-2022)

      • 10.4.7 Indonesia Inactivated Vaccine Consumption (2017-2022)

      • 10.4.8 Thailand Inactivated Vaccine Consumption (2017-2022)

      • 10.4.9 Singapore Inactivated Vaccine Consumption (2017-2022)

      • 10.4.10 Malaysia Inactivated Vaccine Consumption (2017-2022)

      • 10.4.11 Philippines Inactivated Vaccine Consumption (2017-2022)

      • 10.4.12 Vietnam Inactivated Vaccine Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Inactivated Vaccine Consumption (2017-2022)

      • 10.5.2 Colombia Inactivated Vaccine Consumption (2017-2022)

      • 10.5.3 Chile Inactivated Vaccine Consumption (2017-2022)

      • 10.5.4 Argentina Inactivated Vaccine Consumption (2017-2022)

      • 10.5.5 Venezuela Inactivated Vaccine Consumption (2017-2022)

      • 10.5.6 Peru Inactivated Vaccine Consumption (2017-2022)

      • 10.5.7 Puerto Rico Inactivated Vaccine Consumption (2017-2022)

      • 10.5.8 Ecuador Inactivated Vaccine Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Inactivated Vaccine Consumption (2017-2022)

      • 10.6.2 Kuwait Inactivated Vaccine Consumption (2017-2022)

      • 10.6.3 Oman Inactivated Vaccine Consumption (2017-2022)

      • 10.6.4 Qatar Inactivated Vaccine Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Inactivated Vaccine Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Inactivated Vaccine Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Inactivated Vaccine Consumption (2017-2022)

      • 10.7.2 South Africa Inactivated Vaccine Consumption (2017-2022)

      • 10.7.3 Egypt Inactivated Vaccine Consumption (2017-2022)

      • 10.7.4 Algeria Inactivated Vaccine Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Inactivated Vaccine Consumption (2017-2022)

      • 10.8.2 New Zealand Inactivated Vaccine Consumption (2017-2022)

    11 Global Inactivated Vaccine Competitive Analysis

    • 11.1 Johnson & Johnson (US)

      • 11.1.1 Johnson & Johnson (US) Company Details

      • 11.1.2 Johnson & Johnson (US) Inactivated Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Johnson & Johnson (US) Inactivated Vaccine Main Business and Markets Served

      • 11.1.4 Johnson & Johnson (US) Inactivated Vaccine Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Emergent BioSolutions (US)

      • 11.2.1 Emergent BioSolutions (US) Company Details

      • 11.2.2 Emergent BioSolutions (US) Inactivated Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Emergent BioSolutions (US) Inactivated Vaccine Main Business and Markets Served

      • 11.2.4 Emergent BioSolutions (US) Inactivated Vaccine Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 MedImmune (US)

      • 11.3.1 MedImmune (US) Company Details

      • 11.3.2 MedImmune (US) Inactivated Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 MedImmune (US) Inactivated Vaccine Main Business and Markets Served

      • 11.3.4 MedImmune (US) Inactivated Vaccine Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 CSL Limited (Australia)

      • 11.4.1 CSL Limited (Australia) Company Details

      • 11.4.2 CSL Limited (Australia) Inactivated Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 CSL Limited (Australia) Inactivated Vaccine Main Business and Markets Served

      • 11.4.4 CSL Limited (Australia) Inactivated Vaccine Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Serum Institute of India Pvt (India)

      • 11.5.1 Serum Institute of India Pvt (India) Company Details

      • 11.5.2 Serum Institute of India Pvt (India) Inactivated Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Serum Institute of India Pvt (India) Inactivated Vaccine Main Business and Markets Served

      • 11.5.4 Serum Institute of India Pvt (India) Inactivated Vaccine Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 GlaxoSmithKline (UK)

      • 11.6.1 GlaxoSmithKline (UK) Company Details

      • 11.6.2 GlaxoSmithKline (UK) Inactivated Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 GlaxoSmithKline (UK) Inactivated Vaccine Main Business and Markets Served

      • 11.6.4 GlaxoSmithKline (UK) Inactivated Vaccine Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Merck & Co (US)

      • 11.7.1 Merck & Co (US) Company Details

      • 11.7.2 Merck & Co (US) Inactivated Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Merck & Co (US) Inactivated Vaccine Main Business and Markets Served

      • 11.7.4 Merck & Co (US) Inactivated Vaccine Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    • 11.8 Pfizer (US)

      • 11.8.1 Pfizer (US) Company Details

      • 11.8.2 Pfizer (US) Inactivated Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.8.3 Pfizer (US) Inactivated Vaccine Main Business and Markets Served

      • 11.8.4 Pfizer (US) Inactivated Vaccine Product Portfolio

      • 11.8.5 Recent Research and Development Strategies

    • 11.9 Sanofi Pasteur (France)

      • 11.9.1 Sanofi Pasteur (France) Company Details

      • 11.9.2 Sanofi Pasteur (France) Inactivated Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.9.3 Sanofi Pasteur (France) Inactivated Vaccine Main Business and Markets Served

      • 11.9.4 Sanofi Pasteur (France) Inactivated Vaccine Product Portfolio

      • 11.9.5 Recent Research and Development Strategies

    • 11.10 Astellas Pharma (Japan)

      • 11.10.1 Astellas Pharma (Japan) Company Details

      • 11.10.2 Astellas Pharma (Japan) Inactivated Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.10.3 Astellas Pharma (Japan) Inactivated Vaccine Main Business and Markets Served

      • 11.10.4 Astellas Pharma (Japan) Inactivated Vaccine Product Portfolio

      • 11.10.5 Recent Research and Development Strategies

    12 Global Inactivated Vaccine Market Outlook by Types and Applications to 2028

    • 12.1 Global Inactivated Vaccine Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Pediatrics Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Adults Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Inactivated Vaccine Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Medical Center Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Inactivated Vaccine Market Analysis and Outlook to 2028

    • 13.1 Global Inactivated Vaccine Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.2.2 Canada Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Inactivated Vaccine Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.3.2 UK Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.3.3 Spain Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.3.5 France Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.3.6 Italy Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.3.8 Finland Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.3.9 Norway Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.3.11 Poland Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.3.12 Russia Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Inactivated Vaccine Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.4.2 Japan Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.4.3 India Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Inactivated Vaccine Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.5.3 Chile Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.5.6 Peru Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Inactivated Vaccine Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.6.3 Oman Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Inactivated Vaccine Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Inactivated Vaccine Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Inactivated Vaccine Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Inactivated Vaccine Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Inactivated Vaccine

    • Figure of Inactivated Vaccine Picture

    • Table Global Inactivated Vaccine Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Inactivated Vaccine Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Pediatrics Consumption and Growth Rate (2017-2022)

    • Figure Global Adults Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Medical Center Consumption and Growth Rate (2017-2022)

    • Figure Global Inactivated Vaccine Consumption by Country (2017-2022)

    • Table North America Inactivated Vaccine Consumption by Country (2017-2022)

    • Figure United States Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Canada Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Mexico Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Table Europe Inactivated Vaccine Consumption by Country (2017-2022)

    • Figure Germany Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure UK Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Spain Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Belgium Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure France Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Italy Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Denmark Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Finland Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Norway Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Sweden Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Poland Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Russia Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Turkey Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Table APAC Inactivated Vaccine Consumption by Country (2017-2022)

    • Figure China Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Japan Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure India Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure South Korea Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Thailand Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Singapore Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Philippines Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Table South America Inactivated Vaccine Consumption by Country (2017-2022)

    • Figure Brazil Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Colombia Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Chile Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Argentina Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Peru Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Table GCC Inactivated Vaccine Consumption by Country (2017-2022)

    • Figure Bahrain Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Oman Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Qatar Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Table Africa Inactivated Vaccine Consumption by Country (2017-2022)

    • Figure Nigeria Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure South Africa Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Egypt Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Algeria Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Table Oceania Inactivated Vaccine Consumption by Country (2017-2022)

    • Figure Australia Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Table Johnson & Johnson (US) Company Details

    • Table Johnson & Johnson (US) Inactivated Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Johnson & Johnson (US) Inactivated Vaccine Main Business and Markets Served

    • Table Johnson & Johnson (US) Inactivated Vaccine Product Portfolio

    • Table Emergent BioSolutions (US) Company Details

    • Table Emergent BioSolutions (US) Inactivated Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Emergent BioSolutions (US) Inactivated Vaccine Main Business and Markets Served

    • Table Emergent BioSolutions (US) Inactivated Vaccine Product Portfolio

    • Table MedImmune (US) Company Details

    • Table MedImmune (US) Inactivated Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table MedImmune (US) Inactivated Vaccine Main Business and Markets Served

    • Table MedImmune (US) Inactivated Vaccine Product Portfolio

    • Table CSL Limited (Australia) Company Details

    • Table CSL Limited (Australia) Inactivated Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table CSL Limited (Australia) Inactivated Vaccine Main Business and Markets Served

    • Table CSL Limited (Australia) Inactivated Vaccine Product Portfolio

    • Table Serum Institute of India Pvt (India) Company Details

    • Table Serum Institute of India Pvt (India) Inactivated Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Serum Institute of India Pvt (India) Inactivated Vaccine Main Business and Markets Served

    • Table Serum Institute of India Pvt (India) Inactivated Vaccine Product Portfolio

    • Table GlaxoSmithKline (UK) Company Details

    • Table GlaxoSmithKline (UK) Inactivated Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table GlaxoSmithKline (UK) Inactivated Vaccine Main Business and Markets Served

    • Table GlaxoSmithKline (UK) Inactivated Vaccine Product Portfolio

    • Table Merck & Co (US) Company Details

    • Table Merck & Co (US) Inactivated Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Merck & Co (US) Inactivated Vaccine Main Business and Markets Served

    • Table Merck & Co (US) Inactivated Vaccine Product Portfolio

    • Table Pfizer (US) Company Details

    • Table Pfizer (US) Inactivated Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer (US) Inactivated Vaccine Main Business and Markets Served

    • Table Pfizer (US) Inactivated Vaccine Product Portfolio

    • Table Sanofi Pasteur (France) Company Details

    • Table Sanofi Pasteur (France) Inactivated Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi Pasteur (France) Inactivated Vaccine Main Business and Markets Served

    • Table Sanofi Pasteur (France) Inactivated Vaccine Product Portfolio

    • Table Astellas Pharma (Japan) Company Details

    • Table Astellas Pharma (Japan) Inactivated Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Astellas Pharma (Japan) Inactivated Vaccine Main Business and Markets Served

    • Table Astellas Pharma (Japan) Inactivated Vaccine Product Portfolio

    • Figure Global Pediatrics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Adults Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Medical Center Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Inactivated Vaccine Consumption Forecast by Country (2022-2028)

    • Table North America Inactivated Vaccine Consumption Forecast by Country (2022-2028)

    • Figure United States Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Inactivated Vaccine Consumption Forecast by Country (2022-2028)

    • Figure Germany Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Inactivated Vaccine Consumption Forecast by Country (2022-2028)

    • Figure China Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Inactivated Vaccine Consumption Forecast by Country (2022-2028)

    • Figure Brazil Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Inactivated Vaccine Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Inactivated Vaccine Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Inactivated Vaccine Consumption Forecast by Country (2022-2028)

    • Figure Australia Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US